International Delphi Survey – Round 2

MET inhibitor associated peripheral edema in patients with NSCLC – Delphi survey Round 2

Background and objective

This international Delphi survey seeks to develop expert consensus to guide the management of MET inhibitor-associated peripheral edema in patients with advanced/metastatic NSCLC harboring MET alterations (MET exon 14 skipping mutations, MET amplification, MET fusions, or MET overexpression).

Peripheral edema is a common class effect of MET inhibitors, with grade ≥3 events occurring in some patients. It significantly impacts patient quality of life and can lead to dose reductions or treatment discontinuation, potentially compromising outcomes.

Despite its clinical importance, standardized management guidance is lacking. Current approaches – including lifestyle modifications, compression therapy, diuretics, and empirical dose adjustments - vary among clinicians.

This survey uses the Delphi methodology1 to establish expert consensus recommendations to help optimize care for patients with NSCLC harboring MET alterations receiving MET inhibitors.

How this Round 2 works

You are invited to complete Round 2 of this Delphi survey (including 18 questions, 15 minutes to complete). This second-round questionnaire focuses on topics for which consensus was not reached in Round 1, as well as areas that required further clarification based on the first-round responses.

Before answering, you will be provided with aggregated results from Round 1 to inform your judgement. You are invited to reconsider your responses in light of the group feedback while continuing to rely on your own clinical expertise.

As in Round 1, no preparatory work is required, and there are no right or wrong answers. We seek your overall clinical experience and insights - not patient-level data or record review.

All responses remain anonymous and confidential. Only aggregated data will be analyzed and reported.

Thank you again for your valuable contribution to this collaborative initiative.
On behalf of the Steering Committee

Prof. Frank GRIESINGER

Pius-Hospital; University Medicine of Oldenburg, Oldenburg, Germany.

Dr. Terufumi KATO

Clinical Research Center, Tokyo Metropolitan Cancer and Infectious Diseases, Center Komagome Hospital, Tokyo, Japan.

Dr. Claudio MARTIN

Alexander Fleming Institute; Hospital Maria Ferrer, Buenos Aires, Argentina.

Dr. Paul PAIK

Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, United States.

Prof. Giulia PASELLO

University of Padova; Institute Oncology Veneto, Padova, Italy.

Prof. Daniel TAN

National Cancer Center Singapore, Singapore.

This Delphi survey is conducted by Public Health Expertise (PHE), Paris, France and funded by Merck (CrossRef Funder ID: 10.13039/100009945). If you have any questions, please contact: myriam.chebbah@cencora.com. PHE - 10 boulevard de Sébastopol, 75004 Paris.

The email provided for registration and any other personal data will be deleted once the questionnaire is closed. The sponsor will not have access to any personal data.

1 Niederberger, M. & Spranger, J. Delphi Technique in Health Sciences: A Map. Front Public Health 8, 457 (2020).

Before accessing the questionnaire: